Protein & Cell >

2016 , Vol. 7 >Issue 7: 538 - 543

DOI: https://doi.org/10.1007/s13238-016-0281-6

LETTER

Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells

  • Yuan-Qin Yang 1 ,
  • Wen-Jie Dong 1 ,
  • Xiao-Fei Yin 2 ,
  • Yan-Ni Xu 4 ,
  • Yu Yang 5 ,
  • Jiao-Jiao Wang 1 ,
  • Su-Jing Yuan 2 ,
  • Jing Xiao 2 ,
  • Jonathan Howard DeLong 6 ,
  • Liang Chu 2 ,
  • Hai-Neng Xu 7 ,
  • Xiu-Mei Zhou 1 ,
  • Ru-Wei Wang 8 ,
  • Ling Fang 8 ,
  • Xin-Yuan Liu , 1,2 ,
  • Kang-Jian Zhang , 2,3
Expand
  • 1. Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou 310018, China
  • 2. State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
  • 3. Sichuan Huiyang Life Science and Technology Corp., Chengdu 610021, China
  • 4. College of Life Sciences, Northwest Agriculture and Forestry University, Yangling 712100, China
  • 5. Central China Normal University, Wuhan 430079, China
  • 6. Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • 7. Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd., Philadelphia, PA 19104, USA
  • 8. Zhejiang Conba Pharmaceutical Co., Ltd, Hangzhou 310018, China

Published date: 18 Jul 2016

Copyright

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn
Fold

Cite this article

Yuan-Qin Yang , Wen-Jie Dong , Xiao-Fei Yin , Yan-Ni Xu , Yu Yang , Jiao-Jiao Wang , Su-Jing Yuan , Jing Xiao , Jonathan Howard DeLong , Liang Chu , Hai-Neng Xu , Xiu-Mei Zhou , Ru-Wei Wang , Ling Fang , Xin-Yuan Liu , Kang-Jian Zhang . Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells[J]. Protein & Cell, 2016 , 7(7) : 538 -543 . DOI: 10.1007/s13238-016-0281-6

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

DOI

2
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P (2012) Interferon-gamma induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217:385–393

DOI

3
Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD (2011) Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 47:1148–1153

DOI

4
Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjorn M, Kuss M, Liu Y, Porcu G, Kolkova K, Friis Rundsten C (2015) Lack of neuronal IFN-β-IFNAR causes lewy body-and parkinson's disease-like dementia. Cell 163:324–339

DOI

5
Furuta J, Inozume T, Harada K, Shimada S (2014) CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Investig Dermatol 134:1369–1377

DOI

6
Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P (2015) Inducible but not constitutive expression of PDL1 in human melanoma cells is dependent on activation of NF-κB. PLoS One 10:e0123410

7
Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, Li Q, Chen M, Wang L (2014) Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96:284–291

DOI

8
Jin YH, Hou W, Kang HS, Koh CS, Kim BS (2013) The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus. J Virol 87:11538–11551

DOI

9
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80

DOI

10
Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU (2014) Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 92:195–203

DOI

11
Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res 76:227–238

DOI

12
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG (2015) Mechanisms of PDL1/PD-1-mediated CD8 T-cell dysfunction in the context of agingrelated immune defects in the Eμ-TCL1 CLL mouse model. Blood 126:212–221

DOI

13
Noh H, Hu J, Wang X, Xia X, Satelli A, Li S (2015) Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13:14

DOI

14
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

DOI

15
York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH (2015) Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 163:1716–1729

DOI

Options
Outlines

/

〈 〉